Product Description
Pyrimethamine is an antiparasitic prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of Toxoplasma gondiiinfection (toxoplasmosis). Pyrimethamine is usually used together with a sulfonamide (sulfa medicine) to treat toxoplasmosis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimethamine)
Mechanisms of Action: DHFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | India | Indonesia | Ireland | Italy | Jordan | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Slovenia | South Africa | Spain | Sri Lanka | Switzerland | Taiwan | Thailand | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Jordan, Uganda
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Malaria
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04336189 |
DPSP | P3 |
Completed |
Malaria |
2024-07-28 |
2024-08-21 |
||
NCT06522763 |
SUPY-T005 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-08-01 |
12% |
2024-07-27 |
Primary Endpoints|Treatments |